Literature DB >> 10633045

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase.

L Shewchuk1, A Hassell, B Wisely, W Rocque, W Holmes, J Veal, L F Kuyper.   

Abstract

4-Anilinoquinazolines represent an important class of protein kinase inhibitor. Modes of binding for two members of this inhibitor class were determined by X-ray crystallographic analysis of one inhibitor (4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline) in complex with cyclin-dependent kinase 2 (CDK2) and the other (4-[3-methylsulfanylanilino]-6,7-dimethoxyquinazoline) in complex with p38 kinase. In both inhibitor/kinase structures, the 4-anilinoquinazoline was bound in the ATP site with the quinazoline ring system oriented along the peptide strand that links the two domains of the protein and with the anilino substituent projecting into a hydrophobic pocket within the protein interior. In each case, the nitrogen at position-1 of the quinazoline accepted a hydrogen bond from a backbone NH (CDK2, Leu-83; p38, Met-109) of the domain connector strand, and aromatic hydrogen atoms at C2 and C8 interacted with backbone carbonyl oxygen atoms of the peptide strand. The anilino group of the CDK2-bound compound was essentially coplanar with the quinazoline ring system and occupied a pocket between Lys-33 and Phe-80. For the p38-bound inhibitor, the anilino group was angled out of plane and was positioned between Lys-53 and Thr-106 in a manner similar to that observed for the aryl substituent of the pyridinylimidazole class of inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10633045     DOI: 10.1021/jm990401t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP.

Authors:  Yogendra Patel; Valerie J Gillet; Gianpaolo Bravi; Andrew R Leach
Journal:  J Comput Aided Mol Des       Date:  2002 Aug-Sep       Impact factor: 3.686

Review 2.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

3.  Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.

Authors:  Natalie B Vinh; Jamie S Simpson; Peter J Scammells; David K Chalmers
Journal:  J Comput Aided Mol Des       Date:  2012-04-20       Impact factor: 3.686

4.  Structural characterization of proteins using residue environments.

Authors:  Sean D Mooney; Mike Hsin-Ping Liang; Rob DeConde; Russ B Altman
Journal:  Proteins       Date:  2005-12-01

5.  The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors.

Authors:  Alfonso T García-Sosa; Ricardo L Mancera
Journal:  J Mol Model       Date:  2005-12-23       Impact factor: 1.810

Review 6.  Autophagic action of new targeting agents in head and neck oncology.

Authors:  Hidemi Rikiishi
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

Review 7.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization.

Authors:  Julien Michel; Julian Tirado-Rives; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

Review 9.  Structure-based discovery of cyclin-dependent protein kinase inhibitors.

Authors:  Mathew P Martin; Jane A Endicott; Martin E M Noble
Journal:  Essays Biochem       Date:  2017-11-08       Impact factor: 8.000

10.  Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Authors:  Kimberly K Leslie; Michael W Sill; Heather A Lankes; Edgar G Fischer; Andrew K Godwin; Heidi Gray; Russell J Schilder; Joan L Walker; Krishnansu Tewari; Parviz Hanjani; Ovadia Abulafia; Peter G Rose
Journal:  Gynecol Oncol       Date:  2012-08-07       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.